Wake Forest Baptist Health - Hematology Oncology - Statesville

Summary

Wake Forest Baptist Health - Hematology Oncology - Statesville is a medical facility located in Statesville, North Carolina. This center is recognized for care of Skin Cancer, Lung Cancer, Cancer, Melanoma, Cutaneous Melanoma and other specialties. Wake Forest Baptist Health - Hematology Oncology - Statesville is involved with conducting 12 clinical trials across 24 conditions. There are 5 research doctors associated with this hospital, such as Jimmy Ruiz, Michael K. Farris, Michael Goodman, MD, and Pierre L. Triozzi.

Top PIs

Clinical Trials running at Wake Forest Baptist Health - Hematology Oncology - Statesville

Lung Cancer

Melanoma

Cutaneous Melanoma

Non-Small Cell Lung Cancer

Pancreatic Cancer

Bone Metastasis

Cancer

Squamous Cell Carcinoma

Small Cell Lung Cancer

Brain Tumor

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria